PRILOCAINE HYDROCHLORIDE Drug Patent Profile

When do Prilocaine Hydrochloride patents expire, and when can generic versions of Prilocaine Hydrochloride launch?

Prilocaine Hydrochloride is a drug marketed by Septodont Inc and is included in two NDAs.

The generic ingredient in PRILOCAINE HYDROCHLORIDE is epinephrine bitartrate; prilocaine hydrochloride. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the epinephrine bitartrate; prilocaine hydrochloride profile page.

Summary for PRILOCAINE HYDROCHLORIDE

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	101
Clinical Trials:	128
Patent Applications:	301
DailyMed Link:	PRILOCAINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for PRILOCAINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bioprojet	PHASE2
Cairo University	PHASE4
Cairo University	PHASE3

See all PRILOCAINE HYDROCHLORIDE clinical trials

Pharmacology for PRILOCAINE HYDROCHLORIDE

Drug Class	Amide Local Anesthetic
Physiological Effect	Local Anesthesia

Medical Subject Heading (MeSH) Categories for PRILOCAINE HYDROCHLORIDE

Anesthetics, Local

Anatomical Therapeutic Chemical (ATC) Classes for PRILOCAINE HYDROCHLORIDE

N01BB	Amides
N01B	ANESTHETICS, LOCAL
N01	ANESTHETICS
N	Nervous system

US Patents and Regulatory Information for PRILOCAINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Septodont Inc	PRILOCAINE HYDROCHLORIDE	prilocaine hydrochloride	INJECTABLE;INJECTION	079235-001	Sep 29, 2010		RX	No	Yes
Septodont Inc	PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE	epinephrine bitartrate; prilocaine hydrochloride	INJECTABLE;INJECTION	078959-001	Aug 30, 2011	AP	RX	No	No

Prilocaine Hydrochloride Market Dynamics, Patent Status, Competition, and Financial Trajectory

Last updated: September 1, 2026

Prilocaine hydrochloride is a mature, low-cost local anesthetic with limited standalone commercial growth. Its market is fragmented across dental cartridges, injectable anesthetics, topical creams, and combination products such as lidocaine/prilocaine cream. The original branded franchise, Citanest, no longer provides meaningful exclusivity protection in the United States. Current competition is based on manufacturing reliability, regulatory registrations, hospital and dental contracts, formulation performance, and distribution rather than patent differentiation.

Public companies generally do not report revenue for prilocaine hydrochloride as a separate product. Financial exposure is embedded in broader local-anesthetic, dental, hospital-injectable, and topical-anesthetic portfolios. The likely market trajectory is stable to modestly declining for legacy injectable use, with relatively stronger demand for topical lidocaine/prilocaine products and dental formulations.

What is prilocaine hydrochloride used for?

Prilocaine hydrochloride is an amide-type local anesthetic that blocks sodium channels and prevents nerve impulse transmission. It is used for local and regional anesthesia in dental procedures, minor surgery, dermatologic procedures, and topical anesthesia.

The principal commercial formats are:

Product format	Typical use	Market position
Prilocaine hydrochloride injection	Dental and local infiltration anesthesia	Mature generic market
Prilocaine hydrochloride with epinephrine	Longer-duration dental anesthesia and reduced systemic absorption	Dental-focused niche
Lidocaine/prilocaine cream	Topical anesthesia before needle puncture or superficial procedures	More commercially visible combination segment
Dental cartridges	Infiltration and nerve-block anesthesia	Contract, distributor, and dental-channel driven
Compounded or hospital-use preparations	Local anesthesia in institutional settings	Small, fragmented demand

Prilocaine is less dominant than lidocaine because of its narrower commercial footprint and the risk of methemoglobinemia at higher systemic exposure. The FDA label for lidocaine/prilocaine cream warns that prilocaine can contribute to clinically significant methemoglobinemia, particularly in susceptible patients and with excessive dosing.[1]

How large is the prilocaine hydrochloride market?

No authoritative public source provides a consolidated global revenue figure for prilocaine hydrochloride across all dosage forms and manufacturers. Market estimates are difficult to reconcile because analysts may count:

• Prilocaine hydrochloride alone;
• Lidocaine/prilocaine combination products;
• Dental cartridges;
• Hospital injectables;
• Topical prescription products;
• Over-the-counter or pharmacy-dispensed topical anesthetics;
• Contract-manufactured and private-label products.

The standalone active-ingredient market is small relative to lidocaine, bupivacaine, ropivacaine, and articaine. The combination topical segment has greater commercial visibility because EMLA and generic equivalents are marketed across dermatology, pediatrics, outpatient procedures, vaccination-related applications, and venipuncture.

What determines prilocaine hydrochloride revenue?

Revenue is primarily determined by volume and channel access rather than price expansion. The main variables are:

1. Dental procedure volumes and the share of prilocaine-containing cartridges.
2. Hospital and ambulatory surgery purchasing contracts.
3. Availability of lidocaine/prilocaine cream.
4. Generic substitution and tender pricing.
5. Product registrations in individual countries.
6. Manufacturing continuity and supply-chain reliability.
7. Physician preference for alternatives such as lidocaine, articaine, or bupivacaine.

The product has limited ability to command premium pricing unless it is supplied in a differentiated delivery system, a validated combination, or a market with limited registered competitors.

What is the financial trajectory for prilocaine hydrochloride?

The financial trajectory is best characterized as mature, fragmented, and volume-dependent.

Period	Expected market condition	Financial implication
Historical branded period	Citanest and related products carried brand value	Higher pricing and stronger supplier control
Generic transition	Multiple manufacturers and expired core protection	Rapid price compression
Current mature-market period	Stable procedural demand with fragmented supply	Low growth and modest margins
Medium-term outlook	Generic competition continues; topical combinations retain demand	Flat-to-low-single-digit nominal growth in selected channels

Standalone prilocaine hydrochloride revenue is not disclosed by major manufacturers in public filings. AstraZeneca’s historical anesthetic portfolio, including Citanest, is not reported today as a separate active-ingredient revenue line. Current suppliers typically report local anesthetics within broader generic, hospital, dental, or consumer-health categories.

A manufacturer with a low-cost and reliable injectable or dental-cartridge platform may generate recurring cash flow, but the product is unlikely to be a major growth driver. Margin expansion would more likely come from packaging, sterile manufacturing efficiency, geographic expansion, or portfolio bundling than from the active pharmaceutical ingredient itself.

Which companies market prilocaine hydrochloride products?

The competitive field varies by country and dosage form. Known commercial and historical participants include:

• AstraZeneca, historically associated with Citanest and EMLA;
• Aspen PharmaCare and related regional entities;
• Dentsply Sirona and dental-anesthetic distribution channels;
• Fresenius Kabi and other hospital injectable suppliers in selected markets;
• Generic pharmaceutical companies producing topical or injectable formulations;
• Regional contract manufacturers and private-label suppliers.

The exact supplier landscape is country-specific. A company may hold a marketing authorization in one jurisdiction while relying on a contract manufacturer in another. Dental cartridges are particularly dependent on specialized sterile filling, cartridge systems, labeling, and dental-distributor relationships.

How does prilocaine compare with competing local anesthetics?

Attribute	Prilocaine	Lidocaine	Articaine	Bupivacaine
Main commercial use	Dental and topical combinations	Broad local and topical anesthesia	Dental anesthesia	Long-duration regional anesthesia
Market maturity	Mature	Very mature	Strong dental position	Strong hospital position
Standalone differentiation	Limited	Limited but broad	Dental penetration and formulation profile	Duration of action
Key safety consideration	Methemoglobinemia risk	CNS and cardiovascular toxicity at high exposure	Paresthesia and systemic toxicity concerns	Cardiotoxicity and prolonged effect
Patent leverage	Minimal for basic active ingredient	Minimal for basic active ingredient	Product and formulation specific	Product and formulation specific
Commercial growth	Low	Stable	More favorable in dentistry	Stable in hospital procedures

Articaine is a particularly important competitive pressure in dentistry. Lidocaine remains the broadest substitute in injectable and topical applications. Bupivacaine and ropivacaine compete mainly where longer duration is required rather than for routine topical use.

What patents protect prilocaine hydrochloride?

The basic composition-of-matter and use patents for prilocaine hydrochloride are long expired. Prilocaine was developed in the 1960s, and the active ingredient has been commercially available for decades. No commercially meaningful patent exclusivity remains for ordinary prilocaine hydrochloride as an active ingredient.

Potentially relevant patent categories include:

• Formulation patents for lidocaine/prilocaine creams;
• Delivery-device patents covering cartridges, applicators, or topical systems;
• Combination patents involving vasoconstrictors or other active ingredients;
• Manufacturing patents for specific particle sizes, emulsions, or sterile processes;
• Method-of-use patents directed to particular clinical applications.

These rights generally protect a product configuration or use, not prilocaine hydrochloride itself.

What formulations are protected by prilocaine-related patents?

The most commercially relevant formulation history concerns lidocaine/prilocaine topical cream. EMLA contains 2.5% lidocaine and 2.5% prilocaine and was developed as a eutectic mixture that improves topical delivery of both anesthetics.[2]

Any surviving rights around a specific formulation, device, or method would need to be assessed by jurisdiction and claim scope. The underlying combination of lidocaine and prilocaine is not a practical source of broad modern exclusivity by itself. Generic products have entered multiple markets, and the core commercial concept is mature.

Are there active Orange Book patents for prilocaine hydrochloride?

The United States Orange Book is the relevant source for patent and regulatory-exclusivity listings tied to approved prescription drug products. Basic prilocaine hydrochloride products do not have a commercially significant active-ingredient patent estate comparable to newer branded drugs.

For a specific U.S. product, the Orange Book should be checked by application number and product name because listings can differ between:

• Prilocaine-only products;
• Lidocaine/prilocaine combination products;
• Creams;
• Injectable products;
• Discontinued or reference-listed products.

The absence of a current Orange Book patent listing would not eliminate possible formulation, device, manufacturing, or state-law risks outside the Orange Book framework.[3]

When did prilocaine hydrochloride lose exclusivity?

Prilocaine hydrochloride lost practical market exclusivity decades ago. The original innovation period dates to the 1960s, while modern commercial products entered an environment dominated by generic competition, regional registrations, and formulation-level differentiation.

The commercial consequences are clear:

• No current composition-of-matter barrier prevents generic production.
• Basic prilocaine hydrochloride products can compete on price.
• Regulatory approval, sterile manufacturing, and supply continuity are the main entry barriers.
• Topical combination products may retain narrower formulation or regulatory protections depending on the country.
• Brand value persists mainly through recognition, distribution, and clinical familiarity.

Are there Paragraph IV challenges involving prilocaine hydrochloride?

Paragraph IV litigation is unlikely to be commercially material for basic prilocaine hydrochloride because the core active ingredient is long genericized and lacks a contemporary blockbuster patent estate. Paragraph IV activity would be more plausible for a specific branded topical combination, delivery system, or formulation with a listed patent.

For a generic applicant, the more relevant U.S. pathway depends on the reference product:

• An abbreviated new drug application may be available for a conventional generic product.
• A 505(b)(2) application may be used where the product differs in formulation, route, strength, or clinical evidence requirements.
• A topical product may face complex bioequivalence and product-characterization requirements.
• A dental cartridge may require manufacturing and device-related controls in addition to pharmaceutical equivalence.

What is the FDA regulatory status of prilocaine hydrochloride?

Prilocaine hydrochloride and lidocaine/prilocaine products have longstanding FDA regulatory histories. The regulatory status differs by product, sponsor, dosage form, and marketing application.

Important regulatory distinctions include:

1. A product may be FDA-approved but discontinued commercially.
2. A product may appear in FDA databases as discontinued without indicating a safety withdrawal.
3. A topical combination may be approved under a separate application from an injectable or dental product.
4. A foreign-market product may have no U.S. approval.
5. Over-the-counter anesthetic products may fall under different monograph or labeling frameworks.

FDA labeling for EMLA identifies lidocaine and prilocaine as the active ingredients and includes dosing, contraindications, warnings, and methemoglobinemia information.[1] DailyMed provides current or historical labeling records submitted to the National Library of Medicine, but listing status should not be treated as proof of active commercial sales.[4]

What manufacturing and intellectual-property barriers affect market entry?

The main barriers are operational rather than patent-based.

Sterile manufacturing

Injectable prilocaine hydrochloride products require validated aseptic processing, container-closure integrity, stability data, particulate controls, and compliance with current good manufacturing practice. Dental cartridges add specialized filling and inspection requirements.

Formulation reproducibility

Lidocaine/prilocaine cream depends on consistent drug distribution, emulsion performance, pH, viscosity, content uniformity, and skin-delivery characteristics. A generic manufacturer may need extensive comparative characterization even where no blocking patent exists.

Packaging and device integration

Dental cartridges, topical applicators, and occlusive dressings can create device or combination-product requirements. Packaging changes may require regulatory review and can increase development costs.

Supply-chain concentration

Shortages can result from a limited number of qualified sterile manufacturers, changes in active pharmaceutical ingredient supply, container shortages, or failed inspections. These risks can temporarily improve pricing for suppliers with available inventory.

What generic entry risks exist for prilocaine hydrochloride?

Generic entry risk is high for conventional products because:

• The active ingredient is long off-patent.
• Therapeutic substitution is established.
• Multiple local-anesthetic alternatives exist.
• Buyers often use tenders and formularies.
• Physicians generally have several clinically familiar options.

The principal commercial risk is therefore not a single future generic launch. It is persistent price competition from existing generic suppliers.

A new entrant would face the strongest competition in standard injectable formats. A differentiated topical product, dental cartridge, or combination product could have better economics, but it would also face higher regulatory, manufacturing, and commercialization requirements.

What licensing deals affect prilocaine hydrochloride?

No recent, widely disclosed licensing transaction appears to make prilocaine hydrochloride a material standalone asset. Historical rights associated with Citanest, EMLA, and regional local-anesthetic products may have moved through corporate acquisitions, commercial partnerships, or distribution agreements.

Current licensing value is more likely to attach to:

• A proprietary topical delivery system;
• A branded combination product;
• A dental delivery platform;
• A regional marketing authorization;
• A contract manufacturing and distribution arrangement.

For diligence purposes, the active ingredient should be separated from the product rights. A license to sell a prilocaine-containing product may cover trademarks, regulatory dossiers, manufacturing rights, or territory-specific distribution without granting meaningful patent exclusivity.

What patent litigation affects prilocaine hydrochloride?

Prilocaine hydrochloride has no known litigation profile comparable to high-value branded drugs. Litigation exposure is more likely to involve:

• Formulation patents for lidocaine/prilocaine cream;
• ANDA litigation involving a branded topical product;
• Trade dress or trademark disputes;
• Product-liability claims concerning methemoglobinemia or dosing;
• Manufacturing-quality disputes;
• Contract or distribution disagreements.

The absence of major patent litigation does not mean that a particular generic launch is risk-free. A product-specific freedom-to-operate review must cover formulation claims, device patents, regulatory exclusivity, trademarks, and local patent registers.

What is the geographic market outlook?

North America and Europe are mature markets with established generic substitution. Demand is supported by dentistry, outpatient procedures, dermatology, pediatric care, and topical anesthetic use.

Emerging markets may offer greater volume growth because of:

• Expanding dental-care access;
• Growth in outpatient procedures;
• Increased local manufacturing;
• Wider use of topical anesthetics;
• Public and private hospital procurement.

Pricing in emerging markets can remain low because local manufacturers compete aggressively and regulatory standards differ by jurisdiction. Registration complexity, local clinical requirements, import controls, and government tenders often matter more than patent rights.

How strong is the prilocaine hydrochloride patent estate?

The patent estate is weak for the basic active ingredient and stronger only at the product-periphery level.

IP category	Current strength	Commercial relevance
Prilocaine composition of matter	Very weak or expired	None for ordinary generic entry
Basic injectable formulation	Weak	Limited blocking value
Lidocaine/prilocaine cream concept	Mature and crowded	Product-specific relevance
Delivery devices and applicators	Variable	Can delay or complicate entry
Manufacturing processes	Variable	Usually narrow and design-around possible
Trademarks and trade dress	Potentially relevant	Brand and channel protection
Method-of-use claims	Usually narrow	Relevant only to specific approved uses

A prospective entrant should assume no broad patent barrier for conventional prilocaine hydrochloride. The key diligence question is whether the target product reproduces a protected formulation, device, or label rather than whether prilocaine itself remains patented.

What is the likely generic launch scenario?

For a conventional prilocaine hydrochloride injection or dental cartridge, a new entrant could generally pursue a low-price, supply-reliability strategy. The likely launch sequence would be:

1. Confirm the applicable FDA or foreign regulatory pathway.
2. Establish pharmaceutical equivalence and stability.
3. Qualify an API and sterile manufacturing site.
4. Secure cartridge, vial, tube, or applicator capacity.
5. Obtain dental, hospital, or pharmacy-channel contracts.
6. Launch at a discount to incumbent products.
7. Defend share through supply continuity and tender participation.

For a lidocaine/prilocaine cream, development risk is higher because topical bioequivalence and formulation performance can be more complex. Commercial success would depend on product feel, onset consistency, packaging, reimbursement, physician familiarity, and pharmacy access.

Key Takeaways

• Prilocaine hydrochloride is a mature, largely generic local anesthetic.
• The basic active ingredient has no meaningful remaining composition-of-matter exclusivity.
• Citanest no longer provides a significant branded patent barrier.
• Lidocaine/prilocaine cream is the most commercially differentiated product segment.
• Public companies do not disclose reliable standalone prilocaine revenue.
• Financial performance is driven by volume, tender pricing, manufacturing efficiency, and distribution.
• Generic-entry risk is high for conventional injections and dental products.
• The main barriers are sterile manufacturing, topical formulation performance, device integration, and regulatory compliance.
• No major current Paragraph IV or patent-litigation trend appears to define the market.
• The medium-term outlook is flat to modestly declining for standalone injectable use, with better resilience in topical combination and dental channels.

FAQs

Is prilocaine hydrochloride still patented?

The basic prilocaine hydrochloride active ingredient is long off-patent. Any remaining rights are more likely to concern a specific formulation, delivery device, manufacturing process, or method of use.

Is EMLA the same as prilocaine hydrochloride?

No. EMLA contains both lidocaine and prilocaine, each at 2.5% in the conventional cream formulation. Prilocaine hydrochloride is one active component, not the complete EMLA product.[1]

Can a company manufacture generic prilocaine hydrochloride?

Yes, subject to applicable regulatory approval, quality requirements, pharmaceutical equivalence, and manufacturing controls. Injectable and dental products require validated sterile production.

Why is prilocaine less commercially important than lidocaine?

Lidocaine has broader use across injectable, topical, antiarrhythmic, dental, and hospital applications. Prilocaine has a narrower market and carries a recognized methemoglobinemia risk at excessive or susceptible-patient exposures.

Does prilocaine hydrochloride have biosimilar risk?

No. Prilocaine hydrochloride is a chemically synthesized small molecule, not a biologic. The relevant competitive threat is generic substitution, not biosimilar competition.

References

1. U.S. Food and Drug Administration. (2023). EMLA cream prescribing information: Lidocaine and prilocaine cream. FDA.

2. AstraZeneca. (2019). EMLA cream product information. AstraZeneca.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. National Library of Medicine. (2024). DailyMed: Current medication information. U.S. National Library of Medicine.